RETA

Reata Pharmaceuticals, Inc. [RETA] Stock Forecast

Q: What is Reata Pharmaceuticals, Inc. stock symbol ?

Reata Pharmaceuticals, Inc. is a US stock, located in Plano of Tx and trading under the symbol RETA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

RETA Stock Summary

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Became profitable this year

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

RETA has less than 1 year of cash runway

Debt-to-Equity ratio of 1.9 is considered moderate, deeper research suggested.

In the News

RETA Financial details

Company Rating

Strong Buy

Market Cap

6.57B

Income

-80.06M

Revenue

24.4M

Book val./share

2.1

Cash/share

7.96

Dividend

Dividend %

Employees

321

Optionable

Shortable

Yes

Earnings

06 Nov 2023

P/E

-81.11

Forward P/E

PEG

11.34

P/S

269.17

P/B

74.38

P/C

P/FCF

-26.32

Quick Ratio

2.82

Current Ratio

3.21

Debt / Equity

1.9

LT Debt / Equity

EPS (TTM)

-2.33

EPS next Y

EPS next Q

EPS this Y

4.88%

EPS next Y

EPS next 5Y

EPS last 5Y

24.17%

Revenue last 5Y

-47.12%

Revenue Q/Q

11564.62%

EPS Q/Q

-270.67%

SMA20

SMA50

SMA100

Inst Own

84.62%

Inst Trans

1.11%

ROA

-16%

ROE

19%

ROC

-0.16%

Gross Margin

97%

Oper. Margin

-244%

Profit Margin

-328%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

21.83-172.46

52W High

52W Low

RSI

Rel Volume

Avg Volume

954.09K

Volume

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

1.41943

Volatility

0%, 0%

Prev Close

Price

Change

RETA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.93	0.87	0.27	0.32	0.06
Net income per share	-2.91	-9.54	-7.35	-8.19	-8.59
Operating cash flow per share	-3.02	-8.26	-9.56	-6.49	-5.62
Free cash flow per share	-3.05	-8.35	-9.59	-6.53	-5.71
Cash per share	12.19	21.84	24.27	16.25	10.67
Book value per share	-15.17	-23.36	-28.43	-34.57	-1.81
Tangible book value per share	0.55	8.45	12.38	5.12	-1.81
Share holders equity per share	-15.17	-23.36	-28.43	-34.57	-1.81
Interest debt per share	3.64	11.18	3.69	5.3	4.44
Market cap	1.55B	6.22B	4.17B	957.79M	1.38B
Enterprise value	1.3B	5.71B	3.35B	503.57M	1.46B
P/E ratio	-19.29	-21.43	-16.82	-3.22	-4.42
Price to sales ratio	29	234.48	462.04	83.36	622.68
POCF ratio	-18.55	-24.76	-12.93	-4.06	-6.76
PFCF ratio	-18.4	-24.5	-12.89	-4.04	-6.65
P/B Ratio	-3.7	-8.75	-4.35	-0.76	-21
PTB ratio	-3.7	-8.75	-4.35	-0.76	-21
EV to sales	24.17	215.27	371.33	43.83	657.49
Enterprise value over EBITDA	-16.95	-20.08	-14.87	-2.07	-5.42
EV to operating cash flow	-15.46	-22.73	-10.39	-2.14	-7.13
EV to free cash flow	-15.34	-22.49	-10.36	-2.12	-7.02
Earnings yield	-0.05	-0.05	-0.06	-0.31	-0.23
Free cash flow yield	-0.05	-0.04	-0.08	-0.25	-0.15
Debt to equity	-0.23	-0.46	-0.09	-0.11	-1.82
Debt to assets	0.27	0.48	0.1	0.19	0.23
Net debt to EBITDA	3.38	1.79	3.63	1.87	-0.29
Current ratio	6.12	3.49	7.11	11.05	6.75
Interest coverage	-12.45	-25.47	-6.15	-4.6	-6.47
Income quality	1.04	0.87	1.3	0.79	0.65
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.61	2.2	8.33	8.62	49.31
Research and developement to revenue	1.82	4.83	17.64	13.58	76.64
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.01	0	0.01	0.02
Capex to revenue	-0.01	-0.1	-0.1	-0.12	-1.48
Capex to depreciation	-1.58	-2.87	-0.82	-1.1	-2.89
Stock based compensation to revenue	0.2	0.99	6.39	4.94	26.5
Graham number	31.51	70.81	68.56	79.8	18.69
ROIC	0.24	0.75	0.24	0.25	-1.56
Return on tangible assets	-0.23	-0.43	-0.29	-0.4	-0.61
Graham Net	0.28	7.85	11.38	1.14	-5.3
Working capital	286.35M	477.26M	728.14M	542.48M	338.81M
Tangible asset value	15.16M	256.86M	417.43M	185.99M	-65.7M
Net current asset value	12.22M	243.71M	407.17M	47.45M	-182.42M
Invested capital	-0.23	-0.46	-0.09	-0.11	-1.82
Average receivables	0	0	11.11M	11.11M	0
Average payables	3.27M	3.19M	3.35M	9.15M	16.11M
Average inventory	0	0	-11.11M	-11.11M	0
Days sales outstanding	0	0	899.57	0	0
Days payables outstanding	0	5.6	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0.41	0	0
Payables turnover	0	65.2	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0.19	0.41	0.26	0.24	4.75
Capex per share	-0.02	-0.09	-0.03	-0.04	-0.09

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.02	0.01	0.03	0.01	0.55
Net income per share	-2.02	-2.1	-2.35	-3	4.65
Operating cash flow per share	-1.35	-1.27	-1.39	-2.2	-1.68
Free cash flow per share	-1.41	-1.28	-1.4	-2.21	-1.69
Cash per share	13.2	11.93	10.67	8.69	7.96
Book value per share	-38.47	0.12	-1.81	-45.57	2.1
Tangible book value per share	1.88	0.12	-1.81	-3.54	2.1
Share holders equity per share	-38.47	0.12	-1.81	-45.57	2.1
Interest debt per share	4.42	4.14	3.59	3.58	4.19
Market cap	1.11B	918.17M	1.38B	3.36B	4.23B
Enterprise value	1.11B	1.03B	1.46B	3.39B	4.35B
P/E ratio	-3.77	-2.99	-4.03	-7.58	5.48
Price to sales ratio	1.45K	1.7K	1.51K	17.23K	186.06
POCF ratio	-22.56	-19.73	-27.36	-41.24	-60.52
PFCF ratio	-21.56	-19.59	-27.17	-41.17	-60.28
P/B Ratio	-0.79	203.32	-21	-2	48.48
PTB ratio	-0.79	203.32	-21	-2	48.48
EV to sales	1.46K	1.9K	1.59K	17.4K	191.21
Enterprise value over EBITDA	-17.45	-14.61	-20.47	-30.79	-53.68
EV to operating cash flow	-22.63	-22.07	-28.89	-41.65	-62.2
EV to free cash flow	-21.63	-21.91	-28.69	-41.58	-61.95
Earnings yield	-0.07	-0.08	-0.06	-0.03	0.05
Free cash flow yield	-0.05	-0.05	-0.04	-0.02	-0.02
Debt to equity	-0.11	31.16	-1.82	-0.07	1.9
Debt to assets	0.24	0.24	0.23	0.27	0.33
Net debt to EBITDA	-0.06	-1.55	-1.08	-0.3	-1.45
Current ratio	10.6	8.78	6.75	6.09	3.21
Interest coverage	-6.23	-6.62	-6.52	-10.03	24.21
Income quality	0.67	0.59	0.59	0.7	-0.36
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	33	50.5	35.04	281.46	0
Research and developement to revenue	51.62	80.53	51.67	284.5	2.51
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.05	0.01	0.01	0	0
Capex to revenue	-2.98	-0.63	-0.4	-0.72	-0.01
Capex to depreciation	-8.33	-1.25	-1.32	-0.49	-0.94
Stock based compensation to revenue	18.19	26.75	16.39	195.16	0.9
Graham number	41.79	2.42	9.79	55.44	14.83
ROIC	0.06	-0.24	-0.41	0.07	0.53
Return on tangible assets	-0.12	-0.13	-0.17	-0.24	0.38
Graham Net	-2.23	-3.92	-5.3	-7.16	-1.6
Working capital	444.89M	394.39M	338.81M	277.94M	276.76M
Tangible asset value	68.64M	4.52M	-65.7M	-130.67M	87.29M
Net current asset value	-71.7M	-134.02M	-182.42M	-251.71M	-13.45M
Invested capital	-0.11	31.16	-1.82	-0.07	1.9
Average receivables	0	0	0	-2.86M	8.47M
Average payables	8.38M	7.64M	13.11M	16.58M	17.15M
Average inventory	0	0	0	2.86M	4.33M
Days sales outstanding	0	0	0	-2.64K	89.67
Days payables outstanding	0	0	0	0	2.11K
Days of inventory on hand	0	0	0	0	312.98
Receivables turnover	0	0	0	-0.03	1
Payables turnover	0	0	0	0	0.04
Inventory turnover	0	0	0	0	0.29
ROE	0.05	-17	1.3	0.07	2.21
Capex per share	-0.06	-0.01	-0.01	0	-0.01

RETA Frequently Asked Questions

What is Reata Pharmaceuticals, Inc. stock symbol ?

Reata Pharmaceuticals, Inc. is a US stock , located in Plano of Tx and trading under the symbol RETA

What is Reata Pharmaceuticals, Inc. stock quote today ?

Reata Pharmaceuticals, Inc. stock price is $- today.

Is Reata Pharmaceuticals, Inc. stock public?

Yes, Reata Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 954.09K
Market Capitalization 6.57B
Employee 321
CEO Mr. J. Warren Huff
Headquarters Plano,TX,US
IPO Date 2016-05-26
Website https://www.reatapharma.com

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.